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Abstract
The rat LAT-1 (L-amino acid transporter-1) gene is a CD98 light chain highly expressed in cancer and development. As an initial study of
the molecular basis underlying regulation of its expression, we cloned 2 kb of the LAT-1 5P flanking region. Inverse RACE and primer
extension methods were used to define the transcription initiation site at 80 bp upstream from the translational start site. Functional studies
carried out in normal hepatic cells using constructs containing progressive 5P deletion from region 31958 to 3185 showed 3^5-fold
L-galactosidase activities over control. The presence of an activator site(s) between 352 and 3185 was indicated by low activities conferred
by the construct spanning this region. ß 2001 Elsevier Science B.V. All rights reserved.
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TA1 (tumor antigen 1)/LAT-1 (L-type amino acid trans-
porter), whose gene was cloned in our laboratory [1] and
others’ [2], is a recently characterized light chain of the
CD98 complex [3] and a member of the newly described
and growing family of membrane-associated glycoprotein
amino acid transporters [4]. The CD98 complex, which
consists of 4F2 heavy chain and a light chain isoform,
has been ascribed important functions in a variety of cel-
lular processes including lymphocyte activation, integrin
signaling, membrane fusion and amino acid transport [5^
8]. We have demonstrated TA1 overexpression in rat he-
patocellular carcinoma, human colon cancer, and other
primary neoplasias [1,9]. In addition, transient, immediate
upregulation of TA1 was observed in liver regeneration
after partial hepatectomy and toxic injury [10]. Involve-
ment of CD98 light chain in tumor progression is strongly
suggested by a recent study which showed that upregula-
tion of the CD98 complex, but not the CD98 heavy chain
alone, in Balb3T3 cells resulted in tumorigenicity in nude
mice [11].
Recently, we reported that the level of TA1/LAT-1
RNA expression in primary hepatocytes and non-trans-
formed, immortalized hepatic cells can be modulated by
amino acid (arginine) availability [12]. Intriguingly, avail-
ability of arginine also a¡ected amino acid transport prop-
erties in these cells, but not in transformed and tumori-
genic hepatic lines [12]. These data indicate that hepatic
TA1/LAT-1 expression is normally under tight regulation.
However, little is known in terms of the mechanisms
underlying the regulation of TA1/LAT-1. Indeed, informa-
tion regarding molecular regulation of amino acid trans-
porters or mechanisms underlying the adaptive response of
eukaryotic genes to amino acids in the nutrient environ-
ment is generally lacking [13]. Exceptions are the known
transcriptional regulation of mCAT-2 (murine cationic
amino acid transporter-2) [14,15] and the transcriptional
regulation of a well-described amino acid responsive gene,
asparagine synthetase [16]. Two reports have described an
amino acid responsive nucleic acid sequence element in the
amino acid-responsive gene asparagine synthetase [16,17]
and, very recently, a similar element was de¢ned in CHOP
[18], suggesting a novel mechanism of adaptive transcrip-
tional regulation.
To gain insight into the molecular mechanisms under-
lying the regulation of TA1/LAT-1 expression, the LAT-1
gene promoter was isolated. An approx. 2 kb fragment of
the 5P £anking region of LAT-1 gene was cloned from a
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rat genomic library (GenomeWalker kit, Clontech) using a
gene speci¢c reverse primer 5P-CATCATAGTGGGCAC-
CATCATCG-3P. Sequencing of this 2 kb region revealed
an overlap (100% identity) with the 64 bp portion of 5P
UTR in the rat LAT-1 gene sequence from GenBank (ac-
cession No. AB015432). Features of this novel sequence
(GenBank accession No. AF329652), including putative
cis-acting elements predicted by database analysis (Mat-
Inspector and TRANSFAC), are presented in Fig. 1.
To identify the transcription start site in the 5P £anking
region of rat LAT-1 gene, we used both inverse RACE
(rapid ampli¢cation of cDNA ends) (Fig. 2A) and primer
extension (Fig. 2B) methods. The inverse RACE method is
a modi¢ed RACE protocol described by Eyal et al. [19].
Using this method and the reverse primer 5P-CATCA-
TAGTGGGCACCATCATCG-3P (Gibco), cDNA was
synthesized from mRNA of the normal rat hepatic cell
line WB [20] grown in the absence of arginine for 8 h.
Following 5P phosphorylation and single-strand ligation
of cDNA ends, the circular cDNA was used as a template
for PCR using forward and reverse nested primers (for-
ward primers : 5P-AGGGCGAAGGCGTGACCCTG-
CAGC-3P for lane 6 and 5P-AGGCGCGGGAGAAGAT-
GCTGG-3P for lane 5 in Fig. 2A; reverse primer: 5P-
ATGCTCTCGACGTTCCCG-3P for lanes 5 and 6 in
Fig. 2A). The products (lanes 5 and 6 in Fig. 2A) were
sequenced and con¢rmed to be derived from the TA1/
LAT-1 gene. Based on analysis of the PCR product size
and sequencing analysis, the transcription initiation site
corresponds to an A residue 80 bp upstream from the
translation start site.
Using primer extension to identify the transcriptional
start site, the reverse primer 5P-CATCATAGTGGGCAC-
CATCATCG-3P was end-labeled (using [Q-32P]ATP and
T4 Polynucleotide Kinase, Promega). This labeled primer
was then used to reverse transcribe mRNA from WB cells
using Thermoscript (Gibco). The synthesized, radiola-
beled, cDNA was analyzed on a urea/polyacrylamide gel
according to the procedure described by Promega. The
results, shown in Fig. 2B lanes 1 and 2, indicate a 240
bp fragment which corresponds to a calculated transcrip-
tional start site at 80 bp upstream from the translation
Fig. 1. Nucleotide sequence of the 5P £anking region of the rat LAT-1 (L-amino acid transporter-1) gene (GenBank accession No. AF329652). The tran-
scription initiation site, an A residue, is underlined at the +1 position. Putative cis-acting elements predicted by database analysis (MatInspector,
TRANSFAC) are underlined. *AARE, amino acid response element consensus sequence 5P-(A/G)TT(G/T)CATCA-3P [13,17,18].
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start site. Thus, the transcription initiation sites de¢ned by
primer extension and inverse RACE methods are identical.
Numerous potential cis-acting elements were predicted
by database analysis of the 2 kb long 5P £anking region
(MatInspector and TRANSFAC, http://dot.imgen.bcm.
tmc.edu: 9331/seq-search/gene-search.html). These (shown
in Fig. 1) include binding sites for Sp1, AP1 (activator
protein 1), GR (glucocorticoid receptor), and myc/max.
Several potential binding sites for repressor proteins
were also predicted, such as the sites for NEF1 and G¢-
1. Additionally, we found several sites which have 78^
100% identity with the AARE (amino acid response ele-
ment) consensus sequence [13,17,18]. It is currently unclear
which of these putative elements may play a role in tran-
scriptional regulation of TA1/LAT-1 under normal or
pathological conditions.
For functional studies, promoter constructs containing
progressive 5P deletion were made by PCR. The same re-
verse primer 5P-TTCCCGGCTCGGCCTGGATACC-3P
was used for all constructs and various forward primers
were used as follows: 5P-AATTCCCTGGCACCG-
GACCTCC-3P for the 31958/+70 construct, 5P-TTTAG-
CCCTCCGGAAGGACC-3P for the 31472/+70 construct,
5P-AGAGAGTCTTGGGGCTTCCTGG-3P for the 3940/
+70 construct, 5P-GATACAGTCCGCATCATACG-3P
for the 3185/+70 construct, and 5P-TAGCGGGCGGGT-
AACGGTAGC-3P for the 351/+70 construct. The con-
struct 3498/+70 was generated by PCR from the rat ge-
nomic library (GenomeWalker kit, Clontech), using
adaptor primer supplied. Schematics of the constructs
are illustrated in Fig. 3. These constructs were subcloned
into a promoterless pBLUE-TOPO reporter vector con-
taining a downstream lacZ gene (Invitrogen). An active
promoter inserted into pBLUE-TOPO vector drives the
lac gene encoding L-galactosidase enzyme whose activity
can be monitored spectrophotometrically (L-galactosidase
kit, Invitrogen).
All six promoter-reporter constructs as well as an empty
vector (ligated promoterless reporter vector, Fig. 3) were
transfected into the normal mouse hepatic cell line AML
(5^6U106 cells per 100 mm dish) using lipofectamine plus
(Gibco). To normalize for transfection e⁄ciency, the
pGL3-CTL luciferase vector (Promega) under control of
a strong eukaryotic promoter was co-transfected with each
construct. Transfection was carried out in serum-free, anti-
biotic-free DMEM/F12 medium for 3 h. Following trans-
fection, cells were grown in DMEM/F12/10% FBS. At 30^
45 h post transfection, cells were harvested and cell lysates
assayed for L-galactosidase activity (Invitrogen), luciferase
activity (Pharmingen), and protein concentrations (BCA
Fig. 2. Prediction of transcription initiation site by inverse RACE analy-
sis (A) and primer extension method (B). In panel A, lane M1 is
pBR322/HaeIII marker (Sigma) and M2 is 1 kb Plus marker (Gibco).
Lane 0 is the negative control for PCR with no template and lanes 1^3
are PCR products from reactions using single primer (each one of the
reverse or forward primers as described in the text). Lane 4 is an inter-
nal positive control, ampli¢ed from the 180 bp LAT-1 coding region.
Lanes 5 and 6 are products from WB hepatoma mRNAs using forward
and reverse primers as described in the text. In panel B, lane M is the
radiolabeled PX174/HinfI marker (Promega) and lane C is the positive
control from Promega primer extension kit (kanamycin positive control
RNA, 87 bp). Lanes 1 and 2 are primer extension products (240 bp) us-
ing radiolabeled primer as described in the text from WB hepatoma cell
mRNAs (10 Wg and 50 Wg for lanes 1 and 2, respectively).
Fig. 3. Promoter constructs containing progressive 5P deletion and the
corresponding relative activities in K mouse liver (KML) cells. Relative
activity ( þ S.E.M. of 6^10 data points from at least three independent
experiments) is shown as fold activity of each construct relative to the
activity of empty vector-transfected cell lysates. All activities were nor-
malized to transfection e⁄ciency as measured by the luciferase activity
(Pharmingen) of pGL3-CTL (Promega).
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assay, Pharmingen). Results of these reporter assays (ac-
tivities normalized to transfection e⁄ciency) are summa-
rized in Fig. 3. An average of 3.1^5.6-fold activities over
control (empty vector) were seen for the constructs 3185/
+70, 3498/+70, 3940/+70, 31472/+70, and 31958/+70.
The shortest construct (351/+70) showed a low 0.98-fold
activity, indicating that indispensable transcriptional acti-
vator site(s) are present in the region from 352 to 3185.
The longest construct (31958/+70) showed the highest ac-
tivity (5.6-fold), in contrast to the low 1.1-fold activity
shown by the antisense version of this construct. Although
the database analysis indicated putative elements for acti-
vators and repressors in these regions (see Fig. 1), further
studies are needed to establish the interactions between
these elements and the relevant factors.
In summary, we have cloned a 2 kb fragment of the 5P
£anking sequence of the rat LAT-1 gene. To our knowl-
edge, this is the ¢rst report on the cloning of an L-amino
acid transporter gene promoter in any organism. The tran-
scription initiation site was de¢ned at 80 bp upstream
from the translation start site by methods of inverse
RACE and primer extension. Functional reporter analysis
revealed regions which may be indispensable (352 to
3185) to transcriptional activity. This initial analysis per-
mits future detailed examination of the basis for develop-
mental and oncogenic regulation of TA1/LAT-1/CD98
light chain expression and, importantly, for response to
arginine availability observed in non-transformed hepatic
cells [12]. We are interested in the cis-elements and trans-
acting factors which may be involved either directly or
indirectly in LAT-1 transcription and its responsiveness
to arginine. In this context, it is worth noting that se-
quence analysis predicted the presence of binding sites
for factors such as aryl hydrocarbon receptor, which can
be activated by amino acid [21], and upstream stimulatory
factor (USF), which is involved in nutrient responses of
certain liver genes [22]. It is also of interest to note that we
found several sites which have 78^100% identity with the
amino acid response element (AARE) consensus sequence
[13], which was identi¢ed as an essential element in the
regulated expression of the amino acid responsive genes
asparagine synthetase [17] and human CHOP [18]. These
studies are expected to further our general understanding
of tumor-associated gene responses to the nutrient envi-
ronment and may have important implications in dietary
prevention of cancer. This study is supported by NIH
grant No. 1RO1CA73611-01A1, N.L. Thompson, P.I.
We acknowledge Beth McGonnigal for valuable advice.
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